Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Evaluation of matrix microsampling methods for therapeutic drug candidate quantification in discovery-stage rodent pharmacokinetic studies.

Soto M, Pham R, Almon V, Wagner M, Primack R, Ponce M, Meyer J, James CA, Salyers KL, Retter MW.

Bioanalysis. 2014 Aug;6(16):2135-46. doi: 10.4155/bio.14.184.

PMID:
25331858
2.

Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

Jin J, An M, Sapienza A, Aiyar N, Naselsky D, Sarau HM, Foley JJ, Salyers KL, Knight SD, Keenan RM, Rivero RA, Dhanak D, Douglas SA.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3950-4. doi: 10.1016/j.bmcl.2008.06.019. Epub 2008 Jun 10.

PMID:
18573659
3.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

McCleland BW, Davis RS, Palovich MR, Widdowson KL, Werner ML, Burman M, Foley JJ, Schmidt DB, Sarau HM, Rogers M, Salyers KL, Gorycki PD, Roethke TJ, Stelman GJ, Azzarano LM, Ward KW, Busch-Petersen J.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. Epub 2006 Dec 23.

PMID:
17236763
4.

Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.

Miller WH, Manley PJ, Cousins RD, Erhard KF, Heerding DA, Kwon C, Ross ST, Samanen JM, Takata DT, Uzinskas IN, Yuan CC, Haltiwanger RC, Gress CJ, Lark MW, Hwang SM, James IE, Rieman DJ, Willette RN, Yue TL, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1483-6.

PMID:
12668017
5.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

6.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics.

Ward KW, Proksch JW, Salyers KL, Azzarano LM, Morgan JA, Roethke TJ, McSurdy-Freed JE, Levy MA, Smith BR.

Xenobiotica. 2002 Mar;32(3):221-33.

PMID:
11958561
7.

SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR.

Pharm Res. 2001 Sep;18(9):1336-44.

PMID:
11683250
8.

Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.

Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller WH, Huffman WF, Gowen M.

J Bone Miner Res. 2001 Feb;16(2):319-27.

9.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

J Med Chem. 2000 Jan 13;43(1):22-6. No abstract available.

PMID:
10633035
10.

Identification of metabolites of octamethylcyclotetrasiloxane (D(4)) in rat urine.

Varaprath S, Salyers KL, Plotzke KP, Nanavati S.

Drug Metab Dispos. 1999 Nov;27(11):1267-73.

PMID:
10534311
11.

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, Mumaw JA, Newlander KA, Pirhalla JL, Roethke TJ, Salyers KL, Souder PR, Stelman GJ, Smith BR.

Drug Metab Dispos. 1999 Nov;27(11):1232-41.

PMID:
10534306
12.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.

PMID:
10525079
13.

Extraction of octamethylcyclotetrasiloxane and its metabolites from biological matrices.

Varaprath S, Salyers KL, Plotzke KP, Nanavati S.

Anal Biochem. 1998 Feb 1;256(1):14-22.

PMID:
9466793
14.

Reduced ability of rat preantral ovarian follicles to metabolize 4-vinyl-1-cyclohexene diepoxide in vitro.

Flaws JA, Salyers KL, Sipes IG, Hoyer PB.

Toxicol Appl Pharmacol. 1994 Jun;126(2):286-94.

PMID:
8209381
15.

In vitro metabolism of theophylline by rat and human liver tissue.

Salyers KL, Barr J, Sipes IG.

Xenobiotica. 1994 May;24(5):389-99.

PMID:
8079498
16.

Glucuronidation of all-trans-retinoic acid in liposomal membranes.

Salyers KL, Cullum ME, Zile MH.

Biochim Biophys Acta. 1993 Nov 7;1152(2):328-34.

PMID:
8218334
17.

Effect of tetrachlorodibenzo-p-dioxin (TCDD) on the glucuronidation of retinoic acid in the rat.

Bank PA, Salyers KL, Zile MH.

Biochim Biophys Acta. 1989 Oct 13;993(1):1-6.

PMID:
2508757

Supplemental Content

Loading ...
Support Center